Meiji Seika Pharma Supports Lyric Bio in Ig Manufacturing

Meiji Seika Pharma Co., Ltd. announced a strategic equity investment in Lyric Bio, Inc. Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand.

Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor.

This investment will accelerate Lyric Bio’s ongoing R&D activities and implementation of its IVIg manufacturing platform, strengthening the cooperative relationship between Meiji Seika Pharma and Lyric Bio.

Also Read: Numab and Kaken Partner to Develop NM81 for IBD

“We’re thrilled to collaborate with Meiji in driving innovation for IVIg,” said Kayj Shannon, CEO of Lyric Bio. “Their deep expertise and support will be instrumental in helping us lower costs, broaden access, and decrease its dependence on human donors.”

SOURCE: BusinessWire